Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PF-07923568 in Renal Impairment
NCT06037031Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sisunatovir in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at Day 5, Area Under the Curve From Time Zero to Extrapolated Infinite Time at Day 5 and 1 more. Started Oct 2023; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06037031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037031.